iRadimed (NASDAQ:IRMD) Share Price Passes Above 50-Day Moving Average – Here’s Why

iRadimed Corporation (NASDAQ:IRMD) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $98.67 and traded as high as $104.17. iRadimed shares last traded at $100.63, with a volume of 48,779 shares.

Wall Street Analyst Weigh In

IRMD has been the subject of a number of research reports. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Roth Mkm restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, iRadimed has an average rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Stock Up 0.8%

The company’s 50-day moving average is $98.67 and its two-hundred day moving average is $84.88. The company has a market capitalization of $1.28 billion, a P/E ratio of 57.50 and a beta of 1.11.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, sell-side analysts predict that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Monday, February 23rd will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio is presently 38.86%.

Insider Activity at iRadimed

In other news, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. The trade was a 67.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $100.65, for a total transaction of $503,250.00. Following the transaction, the chief executive officer directly owned 2,262,500 shares in the company, valued at approximately $227,720,625. This represents a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 50,000 shares of company stock valued at $4,859,950. 36.80% of the stock is owned by insiders.

Institutional Investors Weigh In On iRadimed

A number of hedge funds and other institutional investors have recently modified their holdings of IRMD. CWM LLC grew its position in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares during the last quarter. Quarry LP purchased a new position in shares of iRadimed in the third quarter worth $40,000. Farther Finance Advisors LLC raised its holdings in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 397 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new stake in iRadimed during the 3rd quarter valued at $47,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.